| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | BLFS | Common Stock | 8,707,165 | 07 Apr 2025 | See footnote | F1, F2 |
| Id | Content |
|---|---|
| F1 | Pursuant to the acquisition of PanThera CryoSolutions, Inc. ("PanThera") by Biolife Solutions Inc (the "Company"), the Reporting Persons ultimately received cash, instead of the shares reported on the original Form 4. Therefore, the original Form 4 is being amended to delete the transaction that was previously reported therein. |
| F2 | The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. |
Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.